The Royal Oak, Michigan-based startup will use the funding to support development and commercialization of its pan-disease diagnostic testing platform.
Under the deal, Mobilion is implementing its SLIM ion mobility technology on Agilent's QTOF mass specs, with a broad commercial launch planned for 2021.
The funding will support the use of a new in situ RNA sequencing technology, STARmap, to build functional maps of the developing brain and brain tumors.
The company will work with the Genome Institute of Singapore to create a test for breast cancer recurrence prediction using its circulating tumor cell platform.
MyHeritage plans to offer Promethease free of charge through the end of this year and to maintain SNPedia as a free resource for academic and non-profit users.
Personalis will analyze samples from the study, evaluating the pharma company's novel therapy INVAC-1 either as a monotherapy or in combination with the TKI ibrutinib.
The firms plan to use Thermo Fisher's Oncomine Dx Target test to identify cancer patients with RET alterations who might benefit from Lilly's LOXO-292.
The partners will use Biolidics' circulating tumor cell retrieval system to evaluate the cells' utility as biomarkers of patient response to cancer treatment.
The company said it will use the funds to repay the $75 million outstanding under its 2018 Note Purchase Agreement, to expand internationally, and on general operations.
Funded projects will look at the combination of imaging and liquid biopsies for monitoring cancer patient responses and the emergence of treatment resistance.
An initial analysis suggests the novel coronavirus from Wuhan that is sickening people might come from snakes, a team of virologists writes at the Conversation.
